> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AbbVie Files BLA for Psoriasis Therapy
- URL: https://www.fdaweb.com/abbvie-files-bla-for-psoriasis-therapy/
- Published: 2018-04-26T12:00:00.000Z
- Updated: 2026-09-15T00:01:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141310

AbbVie has submitted a BLA for risankizumab, an investigational interleukin-23 inhibitor being evaluated for treating patients with moderate to severe plaque psoriasis. The submission is based on data from the global risankizumab Phase 3 psoriasis program evaluating more than 2,000 patients with moderate to severe chronic plaque psoriasis across four Phase 3 studies — ultIMMA-1, ultIMMa-2, IMMhance and IMMvent. “Across all four studies, risankizumab met all co-primary and ranked secondary endpoints with no new safety signals across the Phase 3 program,” the company says. Risankizumab is part of a collaboration with Boehringer Ingelheim, with AbbVie leading future development and commercialization of risankizumab globally.